Journal Article
. 2011 Sep;29(29).
doi: 10.1200/JCO.2010.28.5437.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Wolfgang Eiermann 1 Tadeusz Pienkowski  John Crown  Saeed Sadeghi  Miguel Martin  Arlene Chan  Mansoor Saleh  Sandeep Sehdev  Louise Provencher  Vladimir Semiglazov  Michael Press  Guido Sauter  Mary-Ann Lindsay  Alessandro Riva  Marc Buyse  Philippe Drevot  Henry Taupin  John R Mackey  
Affiliations
  • PMID: 21911726
  •     50 citations

Abstract

Purpose: Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.

Patients And Methods: Women with node-positive, human epidermal growth factor receptor 2-nonamplified, operable BC were stratified by number of axillary nodes and hormone receptor status and were randomly assigned to adjuvant chemotherapy with six cycles of TAC (75/50/500 mg/m² every 3 weeks) or four cycles of AC (60/600 mg/m² every 3 weeks) followed by four doses of docetaxel at 100 mg/m² every 3 weeks (AC>T). After completion of chemotherapy, radiation therapy was given as indicated, and patients with hormone receptor (HR) -positive disease received adjuvant hormonal therapy with tamoxifen and/or aromatase inhibitors.

Results: In 30 months, 3,298 patients were enrolled (n = 1,649 in each arm). The major baseline characteristics were well balanced between the groups. At a median follow-up of 65 months, estimated 5-year disease-free survival rates were 79% in both groups (log-rank P = .98; hazard ratio [HR], 1.0; 95%CI, 0.86 to 1.16), and 5-year overall survival rates for both arms were 88% and 89%, respectively (log-rank P = .37; HR, 0.91; 95% CI, 0.75 to 1.11). TAC was associated with more febrile neutropenia and thrombocytopenia, and AC>T was associated with more sensory neuropathy, nail changes, and myalgia. The incidence of neutropenic infection was similar in both groups.

Conclusion: The sequential and combination regimens incorporating three drugs were equally effective but differed in toxicity profile.

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Michael F Press, Guido Sauter, +17 authors, Dennis J Slamon.
J Clin Oncol, 2010 Dec 30; 29(7). PMID: 21189395    Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, +18 authors, UNICANCER Breast Group.
Oncologist, 2012 May 23; 17(7). PMID: 22610153    Free PMC article.
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
George Fountzilas, Urania Dafni, +18 authors, Meletios A Dimopoulos.
PLoS One, 2012 Jun 09; 7(6). PMID: 22679488    Free PMC article.
Being Pregnant and Diagnosed with Breast Cancer.
Sibylle Loibl, Sileny N Han, Frederic Amant.
Breast Care (Basel), 2012 Aug 09; 7(3). PMID: 22872793    Free PMC article.
Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship.
Graeme J Koelwyn, Michel Khouri, +2 authors, Lee W Jones.
J Clin Oncol, 2012 Oct 10; 30(36). PMID: 23045598    Free PMC article.
Review.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Edith A Perez, Michael F Press, +15 authors, Dennis J Slamon.
Breast Cancer Res Treat, 2013 Feb 20; 138(1). PMID: 23420271    Free PMC article.
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
K H Park, J H Sohn, +12 authors, J H Seo.
Invest New Drugs, 2013 May 17; 31(5). PMID: 23677653
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Alexandra Schönherr, Viktoria Aivazova-Fuchs, +14 authors, Brigitte Rack.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904831    Free PMC article.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.
R Kreienberg, U-S Albert, +3 authors, A Wöckel.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(6). PMID: 24771925    Free PMC article.
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely.
Pharmacoeconomics, 2014 May 27; 32(7). PMID: 24859241
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Review.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Howard M Stern, Humphrey Gardner, +16 authors, Michael F Press.
Clin Cancer Res, 2015 Feb 05; 21(9). PMID: 25649019    Free PMC article.
Management of locally advanced breast cancer-perspectives and future directions.
Konstantinos Tryfonidis, Elzbieta Senkus, Maria J Cardoso, Fatima Cardoso.
Nat Rev Clin Oncol, 2015 Feb 11; 12(3). PMID: 25668732
Review.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Review.
Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse.
Angela Ogden, Padmashree C G Rida, +2 authors, Ritu Aneja.
Cancer Lett, 2015 Jul 18; 367(2). PMID: 26185000    Free PMC article.
Review.
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Takeo Fujii, Fanny Le Du, +6 authors, Naoto T Ueno.
JAMA Oncol, 2015 Sep 25; 1(9). PMID: 26402167    Free PMC article.
Systematic Review.
Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.
Sung-Bae Kim, Yau Tsz Kok, +2 authors, Zhen Zhou Shen.
J Breast Cancer, 2016 Jan 16; 18(4). PMID: 26770242    Free PMC article.
Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.
Romualdo Barroso-Sousa, Danilo D A Fonseca Reis Silva, Joao Victor Machado Alessi, Max Senna Mano.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823678    Free PMC article.
Review.
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
W Janni, N Harbeck, +9 authors, M Kiechle.
Br J Cancer, 2016 Apr 01; 114(8). PMID: 27031854    Free PMC article.
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.
Chang Gon Kim, Joohyuk Sohn, +8 authors, Gun Min Kim.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27064666    Free PMC article.
Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.
Ricardo Fernandes, Sasha Mazzarello, +6 authors, Mark Clemons.
Support Care Cancer, 2016 May 06; 24(8). PMID: 27146496
Systematic Review.
Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.
S Lupichuk, D Tilley, X Kostaras, A A Joy.
Curr Oncol, 2016 Jun 23; 23(3). PMID: 27330344    Free PMC article.
Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma.
Liyu Jiang, Chuyu Jing, +6 authors, Qifeng Yang.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446451    Free PMC article.
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Michael F Press, Guido Sauter, +17 authors, Dennis J Slamon.
J Clin Oncol, 2016 Aug 31; 34(29). PMID: 27573653    Free PMC article.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
K H Park, S Lee, +11 authors, Jae Hong Seo.
Support Care Cancer, 2016 Oct 07; 25(2). PMID: 27709313
Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India.
Jyoti Bajpai, Deepa Susan, +4 authors, Sudeep Gupta.
Indian J Med Paediatr Oncol, 2017 May 05; 38(1). PMID: 28469332    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Review.
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.
B E P J Vriens, I J H Vriens, +9 authors, Breast Cancer Trialists’ Group of the Netherlands (BOOG).
Breast Cancer Res Treat, 2017 Jul 05; 165(3). PMID: 28674765    Free PMC article.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Review.
Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study.
Omar Abdel-Rahman, Winson Y Cheung.
Med Oncol, 2018 Apr 13; 35(5). PMID: 29644504
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis.
Curr Treat Options Oncol, 2018 Apr 18; 19(5). PMID: 29663173
Review.
'The same old story': thoughts on authorized doses of anticancer drugs.
Fausto Meriggi, Alberto Zaniboni.
Ther Adv Med Oncol, 2020 Mar 05; 12. PMID: 32127926    Free PMC article.
Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.
Omar Abdel-Rahman.
Strahlenther Onkol, 2018 Aug 03; 195(4). PMID: 30069737
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
Michael F Press, Jose A Seoane, +14 authors, Dennis J Slamon.
JAMA Oncol, 2018 Dec 07; 5(3). PMID: 30520947    Free PMC article.
Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials.
Christiane Matuschek, David Krug, Rainer J Klement, René Baumann.
Strahlenther Onkol, 2019 Jan 06; 195(4). PMID: 30610353
The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients.
Wanwan Qi, Xiaoyi Wang, +3 authors, Qiao Cheng.
Sci Rep, 2020 Aug 09; 10(1). PMID: 32764734    Free PMC article.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Sherry X Yang, Eric Polley, Stanley Lipkowitz.
Cancer Treat Rev, 2016 Mar 21; 45. PMID: 26995633    Free PMC article.
Highly Cited. Review.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.
Rajkumar Ramaswamy, Nisarg Joshi, Mujtaba A Khan, Seerin Siddhara.
Onco Targets Ther, 2019 Aug 14; 12. PMID: 31406465    Free PMC article.
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy.
Ye Won Jeon, Seung Taek Lim, +2 authors, Young Jin Suh.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154827    Free PMC article.
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
O Abdel-Rahman.
Clin Transl Oncol, 2018 Jun 30; 21(2). PMID: 29956074
Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Y Shen, T Fujii, +5 authors, L Xiao.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242579    Free PMC article.
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Achim Wöckel, Jasmin Festl, +94 authors, Stephanie Stangl.
Geburtshilfe Frauenheilkd, 2018 Dec 26; 78(11). PMID: 30581198    Free PMC article.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Riccardo Lobefaro, Emma Zattarin, +15 authors, Giuseppe Capri.
Ther Adv Med Oncol, 2020 Dec 19; 12. PMID: 33335565    Free PMC article.
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
Andrea Rocca, Pietro Cortesi, +18 authors, Anna Fedeli.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613693    Free PMC article.